Journal of Cardiovascular Disease Research
ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 12, 2025

Critical Pathological Analysis of Fatal COVID-19 Autopsy Findings in cardiac deaths: A Narrative Review of Pathogenesis and Methodological Standards

Dr. Pushpraj Patel,[1] Dr. Anjeney Mishra[2] Dr. Onteddu Sri Harsha[3] * Dr. Akhilesh Patel,[4] Dr. Kaveri Shaw Patel[5]

[1]MBBS, MD, DNB (Cardiology), MNAMS, Interventional Cardiologist, Golden Heart Hospital, Jabalpur, Madhya Pradesh
[2] MBBS, PGDCC, Non Invasive Cardiologist, Golden Heart Hospital, Jabalpur, Madhya Pradesh
[3]MBBS, MD, DNB (Cardiology), Interventional Cardiologist, Golden Heart Hospital, Jabalpur, Madhya Pradesh
[4]MBBS, MD (Pulmonary Medicine), Consultant Pulmonologist, Golden Heart Hospital, Jabalpur, Madhya Pradesh
[5]MBBS, MS (OBS & GYN), Consultant Gynaecologist Golden Women Care Hospital, Jabalpur, Madhya Pradesh

Corrospondin author

Dr Pushpraj patel

Intervention cardiologist

GOLDEN HEART HOSPITAL , Jabalpur, MP

+ 91 – 9407836002

dranjeney@gmail.com

ABSTRACT

This comprehensive review examines COVID-19 autopsy findings, emphasizing systemic microvascular injury driven by immunothrombosis as the central pathogenesis. Autopsies have clarified that fatal COVID-19 primarily results from vascular endothelial damage and widespread microthrombosis rather than direct viral cytopathic effects. The hallmark pulmonary lesion, Diffuse Alveolar Damage (DAD), similarly appears in influenza, suggesting non-specificity, with systemic vascular injury playing a pivotal role in multi-organ failure. The review highlights that traditional diagnostics like electron microscopy are unreliable for viral detection, advocating for immunohistochemistry (IHC) and in situ hybridization (ISH) methods, which provide better specificity when combined with histological data. Small sample sizes, notably in studies of younger decedents, limit the reliability, but findings indicate a disproportionate thrombotic burden in younger patients with comorbidities like obesity and hypertension, often leading to catastrophic events such as mesenteric ischemia. The systemic hypercoagulability in COVID-19 is linked to endothelial ACE2 receptor expression, supporting the concept of immunothrombosis—a systemic, inflammation-driven coagulopathy differing from classical disseminated intravascular coagulation (DIC). Extrapulmonary findings include microvascular brain infarcts and microhemorrhages, correlating with neurological symptoms. The review underscores

the need for standardized international autopsy protocols and improved diagnostic practices for better understanding and management of COVID-19's systemic effects. Overall, understanding that SARS-CoV-2 predominantly induces microvascular injury reshapes clinical strategies toward targeted anti-thrombotic and anti-inflammatory therapies, especially in high-risk groups. Continued pathological research with standardized, detailed protocols is essential for refining therapeutic approaches and understanding long-term sequelae of COVID-19.

key words- young MI, sudden cardiac death, COVID 19, autopsy findings

Chapter 1: Introduction and Conceptual Framework of COVID-19 Pathogenesis

1.1 The Pivotal Role of Post-Mortem Examination in Defining SARS-CoV-2 Pathology

Post-mortem examination was **indispensable** for translating the clinical manifestations of **SARS-CoV-2 infection** (such as ARDS and DIC) into definitive pathological entities. Early clinical descriptions relied on surrogate markers; autopsies provided direct, verifiable evidence delineating patterns of systemic injury. The primary challenge was distinguishing tissue damage from **direct viral cytopathology** versus injury from the **dysregulated host immune response** (termed 'immunothrombosis').

This urgent need for pathological clarity spurred a global drive for post-mortem studies. However, this urgency led to **heterogeneous autopsy practices and reporting standards**, resulting in a "hugely missed opportunity" for rapid, globally comparable data. This underscored the critical need for **standardized international postmortem protocols**.

1.2 Acknowledgment of Data Limitations and Inaccessible Sources

This analysis is based on a critical review of peer-reviewed literature. Due to **inaccessible web sources**, the comprehensive synthesis focuses on three robust sources: a systematic review of cardiac findings (PMC7876291), a case series on younger decedents (PMC8172269), and a comparative study of COVID-19 versus influenza pathology (PMC8239851).

1.3 Core Pathological Hypotheses: Defining the Injury Mechanism

The pathological characterization of fatal COVID-19 focused on two etiological frameworks: direct viral injury or host immune/systemic vascular dysfunction. Autopsy evidence has **strongly supported the latter**, pointing to **systemic microvascular injury** and **'immunothrombosis'** as pivotal mechanisms driving multi-organ failure. The virulence of SARS-CoV-2 appears to lie in its exceptional capacity to trigger a catastrophic coagulopathy and inflammatory response, rather than solely unique tissue tropism.

Chapter 2: Critique of Autopsy Methodologies and Statistical Reliability

2.1 The Challenge of Small Sample Sizes in Case Series Analysis

The detailed analysis of fatal COVID-19 cases in younger patients provided valuable insights, but the reliability of the findings must be interpreted within the constraint of the study design.

The analysis of a cohort comprising only **six patients** ( ) is **exceptionally small** for extrapolating causal relationships or calculating reliable incidence rates. This small sample size introduced a high risk of **selection bias**, potentially only capturing the most severe or atypical cases. Small samples inherently limit the **generalizability and precision** of findings, making estimates of statistical measures (like the striking 67% (4/6 cases) rate of thromboembolism) unreliable and susceptible to random fluctuation. While generating high-impact observations, these results require urgent validation through larger, prospectively designed studies.

2.2 Standardization of Post-Mortem Protocols and Ancillary Diagnostics

Global variation in autopsy quality and reporting consistency significantly hampered early meta-analysis. Common pathological standards are critically needed, particularly for ancillary studies that confirm viral presence and mechanism of injury.

Critical Evaluation of Viral Detection Methods:

- **Immunohistochemistry (IHC) and In Situ Hybridization (ISH):** Both were comparable in identifying infected cells in lung tissue, often noting viral staining even in areas of minimal pathological change. However, **IHC carries a risk of nonspecific staining of bacteria**, common in superimposed infections, potentially overestimating the direct viral contribution. Judicious use of special stains (e.g., Gram stain) is required. ISH, though less accessible, is valuable for resolving diagnostic ambiguities.
- **Electron Microscopy (EM) Rejection:** EM is strongly cautioned against for routine diagnostics. It was found to be **unrevealing in blindly sampled fixed tissues** and is plagued by abundant cellular mimics that can be mistaken for virions.
- **Expert Recommendation:** IHC and ISH are preferred, but correlation with pre-mortem clinical data and characteristic histologic findings (DAD) is often sufficient, mitigating the need for complex ancillary methods in every case.

Method	Primary Finding/Utility	Key Caveats and Limitations	Expert Recommendation
IHC	Comparable to ISH; using nucleocapsid antibodies.	Risk of **nonspecific staining of bacteria** in superimposed infection.	Use cautiously, correlating with routine histology and clinical data.
ISH	Comparable to IHC; highly useful for resolving diagnostic dilemmas.	Requires specialized laboratory expertise and specific reagents.	Recommended for **definitive confirmation** in complex or ambiguous cases.
EM	Unrevealing in blindly sampled tissues.	**Abundant non-viral mimics**; strongly cautioned against.	**Not recommended** for routine viral diagnostics.

Chapter 3: Pulmonary Pathology: Specificity vs. Stereotypical Response

3.1 Diffuse Alveolar Damage (DAD) as the Common Denominator

The lung is the most severely affected organ, with the histological hallmark being **Diffuse Alveolar Damage (DAD)**. DAD in COVID-19 presents in all phases (acute exudative, proliferative, and organizing/fibrotic) often juxtaposed within the same section, correlating with progressive respiratory failure.

3.2 Critical Comparative Analysis: COVID-19 vs. Fatal Influenza

A comparative autopsy series (16 COVID-19 vs. fatal influenza cases) provided a crucial finding: the clinical and histologic features of severe COVID-19 are **fundamentally similar** to those seen in fatal influenza.

The DAD in COVID-19 is often **indistinguishable** from DAD caused by other severe viral infections. This substantial overlap suggests DAD is not a unique, pathognomonic feature of COVID-19 but a **stereotypical host inflammatory response** to severe acute viral lung injury. This shifts the focus from finding a unique pulmonary signature to identifying the **systemic mechanisms** driving SARS-CoV-2 virulence.

Furthermore, **T-cell inflammatory infiltrate composition** (CD4 and CD8 populations) within the lungs showed **no statistically significant difference** between COVID-19 and influenza, suggesting the adaptive immune response follows a conserved pattern. Thrombosis in the

lung vasculature was also **not exclusively specific** to COVID-19, as elevated D-dimers and microthrombi were prevalent in both cohorts. The differentiating factor is the **intensity and systemic breadth** of the coagulopathy, not its mere presence.

Chapter 4: The Systemic Hallmarks: Immunothrombosis and Microvascular Injury

4.1 Endothelial Tropism and Hypercoagulability

The defining feature of fatal COVID-19, differentiating it from severe influenza, is the **intensity and systemic nature of the vascular injury**. Evidence overwhelmingly supports **systemic microvascular injury** and **'immunothrombosis'** as the central mechanism.

The expression of **Angiotensin-Converting Enzyme 2 (ACE2) receptors on endothelial cells** provides the biological plausibility for this vascular tropism, explaining the observed hypercoagulability, DVT, and pulmonary arterial thromboembolism. Post-mortem studies consistently confirmed significant **venous thrombo-embolic disease**, even in patients receiving prophylactic anticoagulation.

4.2 Distinguishing Immunothrombosis from Classical DIC

The COVID-19 coagulopathy differs from classical **Disseminated Intravascular Coagulation (DIC)**. A crucial pathological distinction is the **absence of widespread glomerular capillary thrombi** (Thrombotic Microangiopathy, TMA) in the kidneys of most published COVID-19 cases. This suggests the coagulopathy is **not a generalized consumption disorder** typical of sepsis-induced DIC, but a **localized, inflammation-driven phenomenon characteristic of immunothrombosis**, necessitating specialized therapeutic approaches.

4.3 Extrapulmonary Manifestations of Microvascular Injury

Immunothrombosis affects other vital organs. The **brain** frequently exhibits pathology, with microthrombi resulting in focal microinfarcts and microhemorrhages, providing the pathological substrate for neurological symptoms and stroke. The underlying mechanism is **microvascular occlusion and small-vessel damage** induced by hypercoagulability, rather than solely direct viral invasion.

Chapter 5: Cardiac Pathology: Myocarditis vs. Secondary Damage

5.1 The Prevalence and Paradox of Viral Presence

A systematic review of cardiac autopsies ( ) confirmed a high prevalence of cardiac pathological findings. **SARS-CoV-2 was found within the myocardium of 47%** of examined hearts. However, this high viral presence existed in stark contrast to the finding of true, acute

myocarditis (inflammatory damage leading to myocyte necrosis), which was evident in **only 1.5%** of deceased patients.

5.2 Critical Analysis of Myocardial Injury Mechanism

The significant disparity between viral detection (47%) and inflammatory myocardial damage (1.5%) decisively refutes the hypothesis that acute, classic myocarditis is a dominant cause of cardiac dysfunction and death in the acute phase. The mere presence of viral material does not equate to active, widespread inflammation.

Instead, autopsy evidence points to cardiac injury being overwhelmingly **secondary to systemic stress and microvascular events**. Prevalent findings included cardiac dilatation (20%), acute ischemia (8%), and intracardiac thrombi (2.5%). Cardiac injury is largely driven by: 1) Systemic hypoxia and shock; 2) Supply-demand mismatch/coronary thrombosis; and 3) **Microvascular occlusion secondary to immunothrombosis**.

Chapter 6: Cohort-Specific Pathology: The Younger Patient Paradigm

6.1 High-Risk Comorbidities in Younger Decedents

A case series of six COVID-19 decedents aged **years** demonstrated that fatal outcomes in this "lower-risk" group were strongly associated with specific underlying conditions, including **overweight/obesity, arterial hypertension, asthma, and obstructive sleep apnea (OSA)**. The presence of baseline metabolic and vascular risk factors appears to accelerate and amplify the systemic damage.

6.2 Disproportionate Thromboembolic Burden

The most striking finding was the **disproportionally high prevalence of thromboembolism and ischemic organ damage**, identified in **67% (4/6 cases)**. Immediate causes of death included acute mesenteric ischemia, hemorrhagic shock, heart failure, and multi-organ failure. This high rate of acute thrombotic death reinforces the link between pre-existing endothelial stress (from comorbidities) and the aggressive, inflammatory coagulopathy. This necessitates that younger patients with these specific comorbidities be managed with an exceptionally high index of suspicion for acute thromboembolic events.

Chapter 7: Synthesis, Translation, and Future Directives

7.1 Integrating Autopsy Findings with Clinical Practice (Translational Impact)

Autopsy data establishes a clear pathological narrative for fatal COVID-19: the primary mechanism of mortality is **systemic microvascular failure (immunothrombosis)**, rather than widespread, direct viral cytopathic destruction.

This pathological synthesis profoundly impacted clinical care:

- The confirmed high prevalence of thromboembolism validated the aggressive clinical adoption of **therapeutic anti-coagulation** strategies.
- The distinction between COVID-19 immunothrombosis and classical DIC (evidenced by the rare occurrence of renal glomerular thrombi) suggests that **targeted anti-inflammatory or complement-inhibiting therapies** may be more effective than traditional DIC management.
- The discovery of microvascular injury in the brain validates the need for comprehensive stroke screening in surviving patients.

7.2 Recommendations for Enhanced Post-Mortem Diagnostics

Future pathological research must overcome early methodological limitations:

- **Standardization and Data Collection:** An **international COVID-19 postmortem diagnostic tool or registry** is critically needed to enforce uniform data collection, overcome reporting bias, and facilitate cross-national comparative analysis.
- **Methodological Adherence for Viral Detection:** IHC and ISH remain preferred, but awareness of IHC's risk of non-specific bacterial staining is crucial. The routine use of **Electron Microscopy is strongly discouraged** due to low yield and difficulty distinguishing virions from cellular mimics.

7.3 Conclusions

The detailed analysis of fatal COVID-19 autopsy findings confirms the disease's status as a **severe systemic vasculopathy driven by aggressive immunothrombosis**. While **Diffuse Alveolar Damage (DAD)** is the predominant pulmonary finding, its lack of histological specificity compared to fatal influenza demonstrates that the characteristic virulence of SARS-CoV-2 resides in its profound and often catastrophic effect on the **microvasculature**. Specific vulnerable subgroups, particularly younger patients with underlying metabolic/hypertensive disorders, face a disproportionately high risk for acute thrombotic death. Continued pathological investigation, guided by standardized protocols, is essential for refining therapeutic targets aimed at mitigating the systemic microvascular injury and coagulopathy that define this disease.

References

1 A series of COVID-19 autopsies with clinical and pathologic ... (2021). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC8239851/

2 Assessing and improving the validity of COVID-19 autopsy studies - A multicentre approach to establish essential standards for immunohistochemical and ultrastructural analyses. (n.d.). ResearchGate. Retrieved October 15, 2025, from https://www.researchgate.net/publication/362449128_Assessing_and_improving_the_validity_of_COVID-19_autopsy_studies_-_A_multicentre_approach_to_establish_essential_standards_for_immunohistochemical_and_ultrastructural_analyses

---

3 Autopsy findings in COVID-19-related deaths: a literature review | springermedizin.de. (n.d.). *springermedizin.de*. Retrieved October 15, 2025, from https://www.springermedizin.de/covid-19/autopsy-findings-in-covid-19-related-deaths-a-literature-review/18458492

---

4 COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies ... (2021). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7876291/

---

5 COVID-19: Autopsy findings in six patients between 26 and 46 years ... (2021). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC8172269/

---

6 COVID-19 autopsies: conclusions from international studies - PMC. (2020). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7719010/

---

7 Construct validity with small sample size in mixed method? (n.d.). ResearchGate. Retrieved October 15, 2025, from https://www.researchgate.net/post/Construct_validity_with_small_sample_size_in_mixed_method

---

8 A critical review of autopsy findings in deaths due to COVID-19. (n.d.). *International Journal of Research in Medical Sciences*. Retrieved October 15, 2025, from https://www.msjonline.org/index.php/ijrms/article/download/13683/8779/63193

---

9 View of "Small" sample size | The Southwest Respiratory and Critical Care Chronicles. (n.d.). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/1251/2689

---

10 Why is a small sample size not enough? (2024). *The Southwest Respiratory and Critical Care Chronicles*. Retrieved October 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11379640/

---

11 [Untitled article]. (2023). *Saudi Journal of Health Sciences*, *12*(2), 1-4. Retrieved October 15, 2025, from https://journals.lww.com/sjhs/pages/articleviewer.aspx?year=2023&issue=12020&article=00001&type=Fulltext

Table 1: Evaluation of Ancillary Viral Detection Methods in Autopsy Pathology

Method	**Primary Finding/Utility**	**Key Caveats and Limitations**	**Expert Recommendation (Based on Critique)**
Immunohistochemistry (IHC)	Comparable to ISH in location and cell count; highest sensitivity/specificity using nucleocapsid antibodies.[2]	Risk of nonspecific staining of bacteria, common in superimposed infection.[2]	Use cautiously, correlating results with routine histology and clinical data; less reliable in cases of superimposed infection.[2]
In Situ Hybridization (ISH)	Comparable to IHC; highly useful for resolving diagnostic dilemmas.[2]	Requires specialized laboratory expertise and	High specificity tool; recommended for definitive confirmation of viral presence in

		specific reagents.[2]	complex or ambiguous cases.[2]
Electron Microscopy (EM)	Unrevealing in blindly sampled tissues.[2]	Abundant non-viral mimics; strongly cautioned against for viral detection.[2]	Not recommended for routine post-mortem viral diagnostics.[2]

Table 2: Comparative Pathological Hallmarks: COVID-19 vs. Fatal Influenza

Pathological Feature	**COVID-19 Autopsy Findings**	**Fatal Influenza Autopsy Findings**	**Critical Analysis / Specificity**
Diffuse Alveolar Damage (DAD)	Acute, organizing, and fibrotic phases present.[1]	Acute, organizing, and fibrotic phases present.[2]	Indistinguishable histomorphologically; represents a stereotypical response to severe viral lung injury.[2]
Inflammatory Infiltrate	Similar T-cell rich composition; trend for higher CD4:CD8 ratio.[2]	Similar T-cell rich composition.[2]	No statistically significant difference in composition at sites of acute injury.[2]
Thrombotic Complications	High prevalence of micro- and macro-thrombi (Immunothrombosis).[1]	Elevated D-dimers common;	Coagulopathic changes are not entirely pathognomonic; COVID-19 is differentiated by intensity/extent of

		microthrombi present.[2]	vascular injury and absence of typical DIC.[1]
Hemorrhagic Changes	Less frequent tendency compared to influenza.[2]	Tended to exhibit hemorrhagic changes more frequently.[2]	Potential subtle difference, though not statistically significant in the analyzed cohort.[2]

Table 3: Summary of Key Findings and Limitations in Primary Autopsy Literature

Source	**Study Type & Scope**	**Key Pathological Finding**	**Incidence/Prevalence**	**Critical Limitation/Insight**
PMC8172269 [6]	Case series (N=6, young patients)	Thromboembolism & Ischemic Organ Damage	67% (4/6 cases)	Very small sample size (); high risk of selection bias; statistical results about incidence are unreliable.[6]
PMC7876291 [3]	Systematic Review (N=316, cardiac focus)	SARS-CoV-2 in Myocardium / True Myocarditis	47% / 1.5%	Severe disparity indicates myocardial injury is predominantly secondary (ischemia/shock), not acute inflammatory myocarditis.[3]

PMC8239851 [2]	Case Series (N=16 COVID), Comparative Study	DAD, Histologic Overlap with Influenza	Universal DAD, No significant difference in inflammation	Pulmonary findings are non-specific; the core mechanism of COVID-19 severity must be systemic (vascular).[2]